Circulating hs-CRP as Disease-Modifying Target via Astrocytic Complement C3 Cascade
🧪 Overview
Elevated circulating high-sensitivity C-reactive protein (hs-CRP) functions as a disease-modifying factor through complement-mediated astrocytic activation rather than microglial IL-1β amplification. In this alternative mechanism, circulating hs-CRP binds to complement factor H (CFH) and disrupts complement regulation, leading to excessive C3 convertase activity and local C3a/C5a production within the central nervous system. Astrocytes, which express high levels of complement receptors C3aR and C5aR, become hyperactivated upon exposure to these complement fragments. This astrocytic activation triggers a distinct inflammatory cascade involving upregulation of complement component C3 synthesis and secretion, creating a positive feedback loop that amplifies complement-mediated neuroinflammation. The activated astrocytes also release complement factor B and properdin, further enhancing alternative complement pathway activity. This complement-centric mechanism differs from the traditional IL-1β/TLR4 pathway by operating through the C3/C5 convertase system and primarily targeting astrocytes rather than microglia.
...🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["Circulating hs-CRP Elevation<br/>Systemic Inflammatory Signal"]
B["Microglial Fc/TLR4 Priming<br/>MyD88/NFkB Tone Increased"]
C["pro-IL1B Production<br/>Inflammasome Substrate Accumulates"]
D["NLRP3-Caspase-1 Cleavage<br/>Mature IL-1beta Release"]
E["Feed-Forward Neuroinflammation<br/>Synaptic Stress and Neuronal Injury"]
F["CRP Lowering or IL1B Blockade<br/>Inflammatory Amplifier Interrupted"]
A --> B
B --> C
C --> D
D --> E
F -.->|"blunts"| D
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — CRP
No curated PDB or AlphaFold mapping for CRP yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for CRP → C3 → C3aR/C5aR axis from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CRP → C3 → C3aR.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF systemic inflammation with elevated hs-CRP (>3 mg/L) is treated with a complement C3 inhibitor (e.g., AMY-101) or C5aR antagonist (e.g., avacopan), THEN cerebrospinal fluid C3a/C5a levels and GFAP+ | ≥30% reduction in CSF C3a/C5a concentrations and GFAP immunoreactivity in the intervention group | — no observation — | pending | 0.65 |
| IF astrocyte-specific C3aR/C5aR is genetically ablated (Cre-lox targeting GFAP+ cells) in an LPS-challenge model with elevated human CRP transgenic expression, THEN neuroinflammatory outcomes (GFAP+ a | Astrocyte-specific knockout reduces GFAP+ cells by ≥40%, C3 deposition by ≥35%, and BBB permeability by ≥30% relative to full knockout | — no observation — | pending | 0.55 |
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |